Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Knight Therapeutics (TSE:GUD)
TSX:GUD
Holding TSE:GUD?
Track your performance easily
Earnings Data
Report Date
Mar 20, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
0.02Last Year’s EPS
-0.23Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 08, 2018
|% Change Since: -4.53%
|Next Earnings Date:Aug 09, 2018
Earnings Call Sentiment|Neutral
The earnings call highlighted record revenue growth and successful product launches, along with a strong pipeline. However, challenges such as declining gross margins, decreased adjusted EBITDA, and currency depreciation were noted.Company Guidance
During the Knight Therapeutics Q3 2024 earnings call, the company highlighted robust financial performance and strategic initiatives. For the nine months ending September 30, 2024, Knight reported record revenues of over $271 million and adjusted EBITDA of over $42 million, with a growth of 17% in their innovative promoted portfolio on a constant currency basis. Key products driving this growth included Lenvima, Trelstar, AKYNZEO, and Cresemba, alongside recent launches like Imvexxy and Bijuva in Canada and Minjuvi in Brazil. The company also reported purchasing 437,500 common shares at an average price of $5.65 under their NCIB. The Q3 2024 revenues were over $91 million, a 12% increase from the previous year, with oncology and hematology revenues contributing approximately $37 million, a growth of 18%. Knight's infectious disease portfolio saw revenues of around $34 million, a 16% increase, primarily due to AmBisome orders and Cresemba's growth. Despite currency headwinds, the company maintains its 2024 guidance of $355 million to $365 million in revenues, with adjusted EBITDA expected to be approximately 16% of revenues.Record Revenue and Growth
For the 9 months ended September 30, 2024, Knight Therapeutics delivered record revenues of over $271 million and adjusted EBITDA of over $42 million, with a growth of 17% on a constant currency basis driven by key products.
Successful Product Launches and Pipeline Advancements
The company launched Imvexxy and Bijuva in Canada, Minjuvi in Brazil, and received regulatory approval for Minjuvi in Mexico. The pipeline has been expanded with 18 products expected to generate over $150 million in revenue.
Revenue Growth in Key Segments
Oncology and hematology portfolio revenues grew by 18%, and the infectious disease portfolio grew by 16% compared to the same period last year.
Financial Assets Gain
Knight recorded a total net unrealized gain of $11.7 million on financial assets, driven by the revaluation of Synergy shares following their IPO.
---
TSE:GUD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
TSE:GUD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | C$5.74 | C$5.15 | -10.28% |
| Aug 08, 2024 | C$5.54 | C$5.76 | +3.97% |
| May 09, 2024 | C$5.92 | C$6.10 | +3.04% |
| Mar 21, 2024 | C$5.39 | C$5.23 | -2.97% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Knight Therapeutics (TSE:GUD) report earnings?
Knight Therapeutics (TSE:GUD) is schdueled to report earning on Mar 20, 2025, TBA Not Confirmed.
What is Knight Therapeutics (TSE:GUD) earnings time?
Knight Therapeutics (TSE:GUD) earnings time is at Mar 20, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TSE:GUD EPS forecast?
TSE:GUD EPS forecast for the fiscal quarter 2024 (Q4) is 0.02.
---